Bull case
Zenas BioPharma is supported by compelling Phase 3 INDIGO data showing obexelimab reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference: -11.4; p=0.021) and delivered 12-month flare-free probabilities of 93% and 87% in the open-label extension. Its differentiated bifunctional CD19/FcγRIIb mechanism, non-depleting and reversible design, and at-home subcutaneous dosing strengthen the case for chronic IgG4-RD maintenance therapy, especially as the company estimates ~30–40K prevalent US cases, ~25K diagnosed and treated patients, and a ~$4B commercial opportunity. With the May 27, 2027 PDUFA approaching and additional SLE and vaccine-response data expected in 4Q26, YE26, October 8, and November 10, the stock benefits from multiple catalysts and a large unmet-need backdrop where steroid toxicity and B-cell depletion remain major limitations.